Statins Inhibit Cutaneous Squamous Cell Carcinoma Cells
DOI:
https://doi.org/10.2340/actadv.v104.25097Keywords:
cutaneous squamous cell carcinoma, statins, actinic keratosisAbstract
Abstract is missing (Short communication)
Downloads
References
Eisen DB, Asgari MM, Bennett DD, Connolly SM, Dellavalle RP, Freeman EE, et al. Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol 2021; 85: e209-233.
https://doi.org/10.1016/j.jaad.2021.02.082 DOI: https://doi.org/10.1016/j.jaad.2021.02.082
Pavan LMC, Rêgo DF, Elias ST, De Luca Canto G, Guerra ENS. In vitro anti-tumor effects of statins on head and neck squamous cell carcinoma: a systematic review. PLoS One 2015; 10: e0130476.
https://doi.org/10.1371/journal.pone.0130476 DOI: https://doi.org/10.1371/journal.pone.0130476
Guo C, Wan R, He Y, Lin SH, Cao J, Qiu Y, et al. Therapeutic targeting of the mevalonate-geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer. Nat Cancer 2022; 3: 614-628.
https://doi.org/10.1038/s43018-022-00358-1
Liu Y, Tang W, Wang J, Xie L, Li T, He Y, et al. Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies. Cancer Causes Control 2014; 25: 237-249.
https://doi.org/10.1007/s10552-013-0326-6 DOI: https://doi.org/10.1007/s10552-013-0326-6
Bansal D, Undela K, D'Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One 2012; 7: e46691.
https://doi.org/10.1371/journal.pone.0046691 DOI: https://doi.org/10.1371/journal.pone.0046691
Tamanoi F, Azizian M, Ashrafi M, Bathaie S. Mevalonate pathway and human cancers. Curr Mol Pharmacol 2017; 10: 77-85.
https://doi.org/10.2174/1874467209666160112123205 DOI: https://doi.org/10.2174/1874467209666160112123205
Di Bello E, Zwergel C, Mai A, Valente S. The innovative potential of statins in cancer: new targets for new therapies. Front Chem 2020; 8: 516.
https://doi.org/10.3389/fchem.2020.00516 DOI: https://doi.org/10.3389/fchem.2020.00516
Wang M, Casey PJ. Protein prenylation: unique fats make their mark on biology. Nat Rev Mol Cell Biol 2016; 17: 110-122.
https://doi.org/10.1038/nrm.2015.11 DOI: https://doi.org/10.1038/nrm.2015.11
Atzmony L, Lim YH, Hamilton C, Leventhal JS, Wagner A, Paller AS, et al. Topical cholesterol/lovastatin for the treatment of porokeratosis: a pathogenesis-directed therapy. J Am Acad Dermatol 2020; 82: 123-131.
https://doi.org/10.1016/j.jaad.2019.08.043 DOI: https://doi.org/10.1016/j.jaad.2019.08.043
Wüster J, Heiland M, Nahles S, Preissner R, Preissner S. Statin medication improves five-year survival rates in patients with head and neck cancer: a retrospective case-control study of about 100,000 patients. Cancers (Basel) 2023; 15: 3093.
https://doi.org/10.3390/cancers15123093 DOI: https://doi.org/10.3390/cancers15123093
Guo C, Wan R, He Y, Lin SH, Cao J, Qiu Y, et al. Therapeutic targeting of the mevalonate-geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer. Nat Cancer 2022 Apr 21;3(5): 614-628.
https://doi.org/10.1038/s43018-022-00358-1 DOI: https://doi.org/10.1038/s43018-022-00358-1
Wang A, Stefanick ML, Kapphahn K, Hedlin H, Desai M, Manson JAE, et al. Relation of statin use with non-melanoma skin cancer: prospective results from the Women's Health Initiative. Br J Cancer 2016; 114: 314-320.
https://doi.org/10.1038/bjc.2015.376 DOI: https://doi.org/10.1038/bjc.2015.376
Yang K, Marley A, Tang H, Song Y, Tang JY, Han J. Statin use and non-melanoma skin cancer risk: a meta-analysis of randomized controlled trials and observational studies. Oncotarget 2017; 8: 75411-75417.
https://doi.org/10.18632/oncotarget.20034 DOI: https://doi.org/10.18632/oncotarget.20034
Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005; 19: 117-215.
https://doi.org/10.1111/j.1472-8206.2004.00299.x DOI: https://doi.org/10.1111/j.1472-8206.2004.00299.x
Santa Lucia G, Snyder A, Lateef A, Drohan A, Gregoski MJ, Barton V, et al. Safety and efficacy of topical lovastatin plus cholesterol cream vs topical lovastatin cream alone for the treatment of disseminated superficial actinic porokeratosis. JAMA Dermatol 2023; 159: 488-495.
https://doi.org/10.1001/jamadermatol.2023.0205 DOI: https://doi.org/10.1001/jamadermatol.2023.0205
Additional Files
Published
How to Cite
License
Copyright (c) 2024 Asher Hackett, Avi Adam Cohen, Tal Frenkel Rutenberg, Emmilia Hodak, Lilach Moyal, Lihi Atzmony
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
